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Abstract
Background: This study aimed to answer three questions related to chronic myofascial pain syndrome (MPS): 1) Is
the motor cortex excitability, as assessed by transcranial magnetic stimulation parameters (TMS), related to state-trait
anxiety? 2) Does anxiety modulate corticospinal excitability changes after evoked pain by Quantitative Sensory Testing
(QST)? 3) Does the state-trait anxiety predict the response to pain evoked by QST if simultaneously receiving a heterotopic
stimulus [Conditional Pain Modulation (CPM)]? We included females with chronic MPS (n =47) and healthy controls
(n =11), aged 19 to 65 years. Motor cortex excitability was assessed by TMS, and anxiety was assessed based on
the State-Trait Anxiety Inventory. The disability related to pain (DRP) was assessed by the Profile of Chronic Pain scale for
the Brazilian population (B:PCP:S), and the psychophysical pain measurements were measured by the QST and CPM.
Results: In patients, trait-anxiety was positively correlated to intracortical facilitation (ICF) at baseline and after
QST evoked pain (β =0 . 0 5a n dβ =0.04, respectively) and negatively correlated to the cortical silent period (CSP)
(β =-1.17 and β =-1.23, respectively) (P <0.05 for all comparisons). After QST evoked pain, the DRP was positively
correlated to ICF (β=0 . 0 2)( P<0 . 0 5) .P ai ns c o re sdu ri n gC P Mw e repo s itively correlated with trait-anxiety when it was
concurrently with high DRP (β= 0.39; P=0.02). Controls’ cortical excitability remained unchanged after QST.
Conclusions: These findings suggest that, in chronic MPS, the imbalance between excitatory and inhibitory descending
systems of the corticospinal tract is associated with higher trait-anxiety concurrent with higher DRP.
Keywords: Transcranial magnetic stimulation, Chronic pain, Noninvasive brain stimulation, Neuromodulation, Anxiety,
Myofascial pain syndrome
Background
Pain is not simply determined by the intensity of the
nociceptive stimulus but also by orchestrated mecha-
nisms that work together, including psychological factors
[1]. As one of these psychological factors, anxiety in-
volves both physiological and psychological aspects that
affect the way sensory interpretation occurs [2]. Anxiety
is considered adaptive because a threatening situation
induces body changes that increase the state of arousal.
Anxiety can be presented as a state-anxiety (i.e., referred
to acute situation-driven episodes that fluctuate over time)
or as a trait-anxiety (i.e., a lifelong pattern, in the form of a
personality feature) [3]. Maladaptive anxiety can take over
and have negative effects on people’s lives [4].
These descriptions are consistent with the State-Trait
Anxiety theory, which predicts that individuals with high
trait-anxiety are generally hypersensitive to stimuli and
are psychologically more reactive [3,4]. Anxious patients
present signs of restlessness, sympathetic overactivity,
and resistance to sedation [5]. Thus, similarly to pain
mechanisms, it is conceivable that anxiety is associated
with alterations in brain excitability [5]. Previous reports
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tude was correlated with neuroticism in subjects with
anxiety-related personality traits [6] and that short intra-
cortical inhibition (SICI) was decreased in those with
obsessive-compulsive disorder (OCD) when compared to
subjects who were screened as psychiatrically normal [7].
In the clinical setting, subjects who frequently experi-
ence stress and anxiety have higher predisposition to de-
velop trigger points, which can lead to myofascial pain
syndrome (MPS) [8]. According to epidemiologic stud-
ies, the myofascial trigger points (MTrPs) might be a
source of nociceptive inputs in 30% to 85% of the pa-
tients seeking pain relief [9,10]. A common sign of MPS
is the referred pain to distant somatic structures with
concomitant modifications of superficial and deep sensi-
tivity in the painful areas [11-13]. It has been theorized
that there are two main mechanisms for pain hypersen-
sitivity in muscle pain syndromes: a “bottom-up mech-
anism” in which the process starts and is maintained by
changes in deep peripheral tissues, and the “top-down
mechanism” which claims that the origin lies in the
stress- and pain- regulating systems in the brain [14].
Both mechanisms would induce changes in the excitabil-
ity of nociceptive neurons in the dorsal horn, descending
and ascending corticospinal tracts and cortical structures,
leading to hypersensitization. To study the inhibitory mech-
anisms that modulate pain processing at the spinal cord,
a “conditioned pain modulation (CPM) stimulus” [15]
method has been used in which heterotopic noxious stimuli
applied to a remote area of the body was shown to attenu-
ate the activity of pain-signaling neurons in the spinal
dorsal horn [16-18].
To improve the understanding of the central mecha-
nisms related to anxiety and pain, we assessed cortical
excitability parameters using single and paired pulse trans-
cranial magnetic stimulation (TMS). We hypothesize that
corticospinal excitability is modulated by anxiety favoring
loss of descendent inhibitory influx. The study presented
here aimed to answer three questions: 1) Is the motor cor-
tex excitability, as assessed by transcranial magnetic stimu-
lation parameters (TMS), related to state-trait anxiety? 2)
Does anxiety modulate corticospinal excitability changes
after evoked pain by Quantitative Sensory Testing (QST)?
3) Does the state-trait anxiety predict the response to pain
evoked by QST if simultaneously receiving a heterotopic
stimulus [Conditional Pain Modulation (CPM)]?
Methods
Study design
The study protocol was reviewed and approved by the eth-
ics committee at the Hospital de Clínicas de Porto Alegre
(HCPA) in Porto Alegre, Brazil (Protocol No. 10-0196),
where the study was carried out. All the procedures were
conducted in accordance with the Declaration of Helsinki.
All the subjects gave their written informed consent prior
to participation.
Study sample
Patients were recruited from the general population
using public postings in different health care units and
referrals from physicians in the Chronic Pain Service at
HCPA. Inclusion criteria included right-handed female
subjects aged 19 to 65 years, with a confirmed diagnosis
of MPS in the upper body segment for at least
three months prior to enrollment, and limited routine
activities due to MPS. The limitation in activities was
evaluated by asking subjects specifically for the presence
(i.e., yes or no) of symptoms that interfere with work,
personal relationships, enjoyment of activities, responsi-
bilities at home, personal goals, and clear thinking (i.e.,
problem solving, concentrating, and/or remembering)
during the past three months. Only subjects with the
presence of interference in one or more of the activities
assessed were included. The diagnosis of MPS was con-
firmed by a second independent examiner with more
than 10 years of clinical experience related to chronic
pain. MPS was defined by regional pain, normal neuro-
logical examination, decreased range of motion, stiffness
in the target muscles, presence of trigger points, taut
bands, tender points, palpable nodules, and pain charac-
terized as dull, hollow,o rdeep that exacerbates during
stress. To distinguish neuropathic pain from ongoing
nociception, the Neuropathic Pain Diagnostic Question-
naire (DN4) was applied to all patients. Only those with
a neuropathic component (score greater than or equal to
4) were included [19]. The exclusion criteria included
the presence of any other pain disorder, such as rheuma-
toid arthritis, radiculopathy, and fibromyalgia; previous
surgery on the affected areas; and the regular use of
anti-inflammatory steroids (because it may interfere with
TMS results). In addition, patients with contraindica-
tions for TMS were also excluded [20].
Healthy controls were recruited from the general popula-
tion using public postings as well. They were asked to
complete screening questionnaires, and were excluded if
they were experiencing any painful condition (either acute
or chronic); used analgesics or corticosteroids; had any
rheumatologic, psychiatric, or neurological disorder; had
abused of alcohol or psychotropic substances during the six
months previous to the screening; or if they were using
medications with known effects on the central nervous
system (CNS).
Considering type I and II errors of 0.05 and 0.20, re-
spectively, and anticipating an effect size (f
2) of 0.25 for
multiple regression analysis allowing for two predictors
(Post-hoc Statistical Power Calculator for Hierarchical
Multiple Regression: http://www.danielsoper.com/stat-
calc3/calc.aspx?id=17 [21], the sample size of 42 patients
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as to account for unexpected factors that would decrease
study power such as increased variability of our sample
or missing data. In fact, a sample of 47 patients would
detect an effect size for correlations of 0.25 with a power
of 84% at a 0.05 alpha level.
Assessments
Demographic characteristics, depressive symptoms, pain-
related catastrophic thinking and anxiety
Demographic information was gathered using a standard-
ized questionnaire. All the psychological instruments used
in this study have been validated for the Brazilian
population and were applied by trained evaluators. The
instruments have been validated by our group [22,23].
Pain-related catastrophic thinking was assessed using the
Brazilian Portuguese Catastrophizing Scale (B-PCS) [22].
The disability related to pain (DRP) in terms of severity,
interference with daily activities, and emotional burden
was evaluated using the Profile of Chronic Pain: Screen
for a Brazilian Population (B-PCP:S) [23]. An accepted cri-
terion to define disability related to pain is a chronic or re-
current pain or discomfort causing restriction [23], thus
we assumed that higher scores on the B-PCP:S indicated
higher disability or functionality at work, at home, during
social situations and/or a higher emotional burden. The
Beck Depression Inventory was employed to assess de-
pressive symptoms [24]. The sequence of assessments is
presented in Figure 1. Healthy controls underwent the
same sequence of assessments, excepting the question-
naires regarding pain and depression; the conditioned pain
modulation test and the TMS paired pulse assessments.
a) Anxiety was measured with the State-Trait Anxiety
Inventory (STAI), adapted to Brazilian Portuguese
[25]. State-anxiety (a situation-driven transient anxiety)
and trait-anxiety (stable personality disposition
reflecting general level of fearfulness) were evaluated.
When answering the S-Anxiety Scale, subjects chose
the number that best describes the intensity of their
feelings in a four-point Likert scale, as follows: (1) not
at all, (2) somewhat, (3) moderately, (4) and very
much so, for 13 different items. When answering the
T-Anxiety Scale, subjects rate the frequency of their
feelings through 12 different items using the following
four-point Likert scale: (1) almost never, (2) sometimes,
(3) often, (4) almost always. Because the Rash analysis
pooled two optios for some of the items of the STAI,
some of the questions in the reduced version are rated
as sometimes (2)/often (3). Item scores are added to
obtain subtest total scores, taking into account that 10
out of 25 responses should be reversed for the anxiety-
absent questions. The S-Anxiety scale score ranges
from 13 to 52, and the T-Anxiety scale score ranges
from 12 to 36. Higher scores denote higher levels of
anxiety.
b) The global intensity of pain was measured with the
Visual Analogue Scale (VAS). The scores for pain
range from 0 (no pain) to 10 (worst pain possible).
c) Quantitative Sensory Testing (QST) was used to
assess heat pain thresholds using the method of
limits with a computer Peltier-based device ther-
mode (30 × 30 mm) [26] that was attached to the
skin on the ventral aspect of the mid-forearm. The
baseline temperature was set at 32°C and was
Figure 1 Flow of sequence of study steps.
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The patient had to report when she began to feel a
warm sensation and when it became painful, with
the latter representing the heat pain threshold
(HPT). Three assessments were performed with an
inter-stimuli interval of 40 seconds [26]. Each
subject’s HPT was defined as the mean painful
temperature of the three assessments. The position
of the thermode was slightly altered between trials
(although it remained on the left ventral forearm) to
avoid either sensitization or response suppression of
the cutaneous heat nociceptors.
d) QST during cold water immersion (CPM-TASK):
The temperature at which subjects felt 6/10 on the
numerical pain scale (NPS) ranging from 0 (no pain)
to 10 (the worst pain imaginable) was assessed. By
measuring QST during cold-water immersion, we
evaluated the degree to which pain perception is
modulated following the presentation of an initial
heterotopic noxious stimulus (Conditional Pain
Modulation - CPM). Subjects immersed their non-
dominant hands into cold water (zero to one degree
Celsius) for one minute. The QST procedure was
administered after 30 seconds of the cold-water
immersion. During this test, subjects were asked to
rate the pain of the stimulated hand using the same
NPS. The temperature was held constant during the
experiment for each subject. Differences (presented
in percentage) between the average pain rating be-
fore and after cold water immersion was defined as
the CPM.
e) Analgesic use was defined as the self-reported aver-
age of analgesics used per week during the last three
months. For data analysis, analgesic use was in-
cluded as a dichotomous variable in which the use
of analgesics less than four days per week was coded
as zero (reference value) and their use on more than
four days per week was coded as one. This strategy
was chosen because subjects with chronic pain
typically use rescue analgesics irregularly and their
frequency of use changed each week according to
their pain level.
Cortical excitability
Transcranial Magnetic Stimulation (TMS) of the left motor
cortex (M1) was performed using a MagPro X100 stimula-
tor (MagVenture Company, Lucernemarken, Denmark)
through a figure-of-eight coil (MagVenture Company). It
was assessed at baseline, at QST assessment and after the
CPM intervention. Ag-AgCl electrodes were placed over
the first dorsal interosseus (FDI) muscle belly and its corre-
sponding tendon on the distal phalanx of the index finger.
Responses to stimuli were recorded from the FDI muscle of
the right hand by surface electromyography (EMG).
The subjects were seated in a comfortable chair and
were informed about the TMS procedure, including all
sensations that may be felt. The amplitudes of single and
paired pulse TMS and the latency of cortical silent
period were measured during the experiment and re-
corded on a excel spreadsheet. Data were analyzed off-
line on a personal computer.
The coil was placed tangentially to the scalp over the
left M1, with an angle of 45° to the sagittal line to iden-
tify the motor “hot spot”, which was defined as the coil
position over the left M1 in which the lowest Motor
Threshold (MT) intensity was required to elicit an ac-
ceptable response in at least 50% of the evoked poten-
tials of the resting FDI [27,28]. This site was marked
with a soft-tipped pen to ensure a constant placement of
the coil throughout the TMS assessments. First, the
motor threshold (MT) was determined, which was de-
fined as the lowest stimulus intensity sufficient to elicit a
response of at least 5 of 10 evoked potentials (at least
50% of successive trials) with minimum amplitude of
50 μV peak-to-peak in the resting FDI [27,28]. Then,
single-pulse measures including the Motor Evoked Po-
tential (MEP) and Cortical Silent Period (CSP) were re-
corded at an intensity of 130% of the MT. The MEP
value was the one that elicited the evoked potential with
1 mV peak-to-peak amplitude. The means of ten con-
secutive trials were recorded. For the CSP the patients
were instructed to perform isometric voluntary contrac-
tion with approximately 10% of maximal contraction of
the FDI. The transient silence in isometric voluntary
EMG activity was elicited in the tonically contracting
FDI muscle with about 10% of the maximal voluntary
contraction; the CSP was preceded by the MEP [29].
Also, ten consecutive trials were recorded. Paired-pulse
measures including the Short Intracortical Inhibition
(SICI) with interstimuli interval of 2 ms and Intracortical
Facilitation (ICF) with interstimuli interval of 12 ms.
The first sub-threshold stimulus was set at 80% of the
individual MT, and the second supra-threshold stimulus
was set at 130% of the MT. The intensity of supra-
threshold test stimuli was adjusted to elicit test stimuli
with peak-to-peak amplitude of about 1 mV. The reduc-
tion of the test MEP elicited by TMS is considered to re-
flect inhibition at the primary motor cortex [30], and
increments of the test MEP elicited by TMS are consid-
ered to reflect facilitation at the primary motor cortex
[31]. Thirty recordings (ten for each SICI, ICF, and test
stimuli) were made in random order having an interval
of approximately 8 seconds between each pulse. Paired-
pulse measures were analyzed calculating their individ-
ual index (Mean SICI/Mean of test stimuli; Mean ICF/
Mean of test stimulus) [30,32]. The same MT value was
used to elicit MEP, CSP, SICI and ICF at baseline, at
QST assessments and after the intervention.
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stimuli interval of 40 seconds and the MEP was assessed
shortly after these measurements. The same researcher
performed the TMS assessments for each patient intend-
ing to reduce potential between-evaluators variability.
Statistical analyses
Descriptive statistics were used to summarize the main
features of the sample. Continuous data were evaluated
for normality using Skewness/Kurtosis tests. After veri-
fying the corresponding assumptions, linear regression
analysis with forward selection controlling for collinearity
[33] was used to identify potential confounding factors in
the association between the main independent variables of
interest, state-trait anxiety, and the dependent variables
M T ,M E P ,I C F ,S I C Ia n dC S P .T h ec o v a r i a t e si n c l u d e di n
the models were age, depressive symptoms, and catastro-
phizing thinking due to chronic pain. Only covariates
retained in each one these models (Table 1) were included
in a final multivariate linear regression model with cortical
excitability parameters as dependent variables (i.e., MT,
MEP, CSP, SICI and ICF) and age, pain on the B:PCP:S and
trait-anxiety as independent variables. The B:PCS was ex-
cluded after collinearity with the B:PCP:S was identified.
The change in MEP was calculated as the standardized
mean difference (SDM) expressed as a percentage (%)
following the formula [(MEP before QST evoked pain
minus MEP after)/(Standard deviation of the MEP be-
fore QST evoked pain)] multiplied by 100. The percent-
age of the MEP change was defined as a dependent
variable. Thus, a multiple regression analysis was run to
assess the association between the percentage of MEP
change and trait-anxiety, adjusting for B-PCP:S and age.
The changes in MEP before and after QST evoked
were compared using a paired t-test. Additionally, the
relationships between CPM, trait-anxiety, DRP and
number of days analgesics used per week in the last
three months (< 4 times/≥4 times) were assessed using
multiple linear regression models. The data was ana-
lyzed using SPSS version 18.0 (SPSS, Chicago, IL).
Results
We screened 62 potential participants with a diagnosis
of MPS, and forty-seven of them were included in the
study. The reasons for exclusion were not fulfilling
diagnostic criteria for MPS, lack of disability as defined
in the protocol, inability to demonstrate a neuropathic
component as assessed by DN4 (Neuropathic Pain
Diagnostic Questionnaire) or the presence of another
diagnosis (fibromyalgia).
All subjects who enrolled also concluded the study and
were included in all the analyses (Table 2). Motor cortical
excitability parameters are presented in (Table 3).
In Figure 2 are presented the MEP amplitude in mV,
before and after QST of a representative patient. This
data presented is an average of 10 trials before and after
QST. Patients presented higher MEPs amplitudes after
QST in relation to the amplitudes before.
Eleven healthy controls with mean (standard deviation)
age of 26.27 (6.31) were recruited. Their mean trait-anxiety
score was 17.18 (3.43), and state-anxiety score 21.55 (4.72).
Their MEP remains unchanged before and after the QST
(P>0.05) (Figure 3).
Relationship between motor cortex excitability and
state-trait anxiety level
As described in the statistical analysis section, poten-
tial confounding factors in the relationship between
the independent variables of major interest (state-trait
anxiety) and the cortical excitability parameters [MT
(resting motor threshold), MEP, ICF, ICI and CSP]
were identified using linear regression model analysis
(Table 1). When the outcome variable was the MEP, no
other variables were retained in the model.
The multivariate linear regression model with the cor-
tical excitability parameters obtained at baseline (before
QST evoked pain) as dependent variables (MT, MEP,
ICF, SICI, CSP) using age, trait-anxiety and pain on B:
PCP:S as independent variables (Table 4). This analysis
revealed a significant relationship between trait-anxiety
and cortical excitability measurements (Wilks’ λ=0.84, F
(34) = 34.7, P <0.0001). The power of this analysis was
0.84. Table 4B presents the results of the multivariate re-
gression model between cortical excitability parameters
(MEP, ICF, SICI, CSP) after QST evoked pain using age,
trait anxiety and score on B:PCP:S as independent
variables. In both conditions, at baseline (before QST
evoked pain) and after QST evoked pain, the trait-
anxiety was associated with motor cortex disinhibition,
Table 1 Linear regression of the relationship between
cortical excitability parameters and potential confounding
factors (n =47)
Parameter SEM β
a t P
Motor Threshold
Age (years) 0.09 0.31 2.15 0.03
Short Intracortical inhibition
(ratio: SICI/test stimulus)
Brazilian Portuguese Catastrophizing
Scale (B-PCS)
−0.005 −0.44 −3.24 0.002
Intracortical facilitation
(ratio: ICF/test stimulus)
Trait-anxiety 0.011 0.56 4.48 0.001
Cortical silent period
Trait-anxiety 0.39 −0.41 −2.95 0.005
aValue adjusted by multiple regression analysis with a stepwise forward method
controlling for collinearity. The covariates included in each model were: state-trait
anxiety, pain-related catastrophic thinking, depressive symptoms and age.
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negative correlation with CSP (Table 4). Also, the ICF
was positively correlated with DRP after the QST evoked
pain (Table 4). This analysis revealed a significant rela-
tionship between trait-anxiety and cortical excitability
(Wilks’ λ =0.80, F (4)=38, P< 0.0001). The power of
this analysis was 0.80.
Relationship between anxiety and the corticospinal
modulatory system
The relationship between trait-anxiety and the change in
MEP (pre to after QST evoked pain) was analyzed in the
regression model using the latter as the dependent
variable. The independent variables were age and pain as
reported on the B-PCP:S (Screen for a Brazilian Popula-
tion). The MEP amplitudes was significantly associated
with trait-anxiety: F (48,1)=5.86, β= 0.36; t= 2.42, P =
0.02. The independent variable retained in the model
was the trait-anxiety. The positive correlation between
trait-anxiety and the MEP indicates that higher trait-
anxiety scores are associated with a greater change on
the MEP amplitudes after QST evoked pain. The trait-
anxiety explained 36% of the variance in the MEP ampli-
tude induced by QST evoked pain.
The effect of the QST evoked pain on the corticosp-
inal modulatory system was evaluated by comparing data
before and after the QST evoked pain (Figure 2). There
was an increase in MEP amplitudes after the QST
evoked pain (P <0.05), indicating the higher excitability
of the motor cortex. The increased intracortical inhib-
ition induced by CPM was demonstrated by a higher
pain threshold during the CPM-TASK, as shown by
lower pain scores on the NPS when compared to the
NPS evoked by the QST alone (P<0.001) (Figure 3).
Effects of analgesics on the relationship between anxiety
and the corticospinal modulatory system
The relationship between the percentage in pain reduc-
tion in NPS with trait-anxiety and DRP is presented in
Figure 4. It was observed an inverse correlation between
NPS during CPM-TASK in both DRP and trait-anxiety.
This association between CPM, trait-anxiety and DRP
observed in this univariate analysis was confirmed using
multiple linear regressions (Table 5). This multivariate
analysis confirmed that there is a significant inverse
correlation between NPS during CPM-TASK and DRP,
whereas the trait-anxiety was marginally significant
(P=0.05, see Table 5). A significant interaction between
trait-anxiety and DRP was detected, when adjusting for
this interaction one unit increment on this product
(trait-anxiety vs. DRP) was associated with 39% incre-
ment on the NRS (P= 0.02) (Table 5). That is, the effi-
ciency of the corticospinal system was reduced for
modulating the pain evoked by QST. Also, this model
showed that analgesics use did not change the relation-
ship between anxiety levels and corticospinal excitability
(P>0.05).
Discussion
This study suggests that there is a relationship between
motor cortex excitability and trait-anxiety. We found a
positive correlation between trait-anxiety, the DRP and
Table 2 Sample characteristics
Variables Mean (SD) or
percentage
Median (Q25,
Q75)
Age (years) 47.28 (11.51) 48 (39, 56)
Marital status (married/
unmarried)
15/47 (yes: 31.91%) —
Weight (kg) 65.69 (11.59) 65 (56.5, 75)
Height (m) 1.62 (0.17) 1.6 (1.56, 1.64)
Education (years) 13.19 (4.20) 13 (11, 16)
Trait-anxiety 23.89 (6.90) 22.5 (19, 29)
State-anxiety 28.22 (7.80) 26 (22, 34)
Beck depression inventory 15.02 (9.27) 13.5 (9, 19)
Brazilian Portuguese
Catastrophizing Scale
(B-PCS)
29.36 (12.59) 33 (20, 39)
Pain lasting longer than
one year (yes/no)
40/48 (yes: 83.33%) —
Total score on the Profile
of Chronic Pain: Screen
for Brazilian population
(B-PCP:S)
59.70 (15.75) 62 (49, 71)
Score on B-PCP:S domains
Intensity 24.6 (3.3) 25 (23, 27)
Interference in daily
activity
21.98 (9.35) 24 (18, 30)
Emotional burden 13.11 (6.24) 13 (9, 18)
Number of days analgesics
were used per week in
the last three months
(< 4 times/≥ 4 times)
a
22/47 (< 4 times:
46.81%)
—
Smoking (yes/no) 26/47 (yes: 55.32%) —
Alcohol consumption
(yes/no)
26/47 (yes: 55.32%) —
Presence of other
chronic diseases
before appearance
of pain (yes/no)
b
21/47 (yes: 44.68%) —
Diagnosis of psychiatric
disorders (yes/no)
18/47 (yes: 38.30%) —
Active use of central
nervous system
medication (yes/no)
c
4/47 (yes: 8.51%) —
aThe same patient may have used more than one medication.
bChronic diseases other than pain: hypertension (n=12); ischemic heart disease
(n=1); heart attack (n=1); diabetes mellitus (n=5); thyroid diseases (n=2);
other chronic diseases listed (n=0).
cCentral nervous medication: tricyclic antidepressant (n = 2); topiromate (n = 1)
tylex (n = 1).
Data presented as Mean (SD) or median (interquartile) or proportion (n =47).
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CSP. Additionally, we observed that when high trait-
anxiety concurs with DRP, the effect of the heterotopic
noxious stimulus on the pain induced during the QST
was reduced (Table 5). High trait-anxiety is positively
correlated with increased cortical excitability and de-
creased intracortical inhibition as assessed by ICF and
CSP (Table 4).
According to previous reports, the inhibitory deficits me-
diated by GABAergic receptors associated with manifesta-
tions of anxious behavior are coherent with our findings
[6,34,35]. A marked increase in ICF has been demonstrated
in drug-naive subjects suffering post-traumatic stress dis-
o r d e r( P T S D )[ 3 6 ] ,a sw e l la sas h o r tC S Pi np a t i e n t sw i t h
obsessive-compulsive disorder [7]. Although the underlying
mechanism is not clear, several neurobiological processes
may explain these findings, as follows. The ICF originates
from excitatory postsynaptic potentials (PSPs) mainly medi-
ated by glutamatargic NMDA receptors [37]. Their latency
is about 10 ms, consistent with the time course of intracor-
tical facilitation [38]. Pharmacological studies support such
Figure 2 Example of 10 averaged transcranial magnetic stimulus-
induced Motor Evoked Potentials at the First Dorsal Interosseus
(FDI), before (MEP) and after (MEPQST) the Quantitative Sensory
Testing (QST).
Figure 3 Changes on cortical excitability and pain during the
QST and CPM-TASK. (A) Motor-evoked potentials (MEP) expressed
in mV, evoked by a stimulus of 130% of the rMT, before and during
the heat pain threshold induced by the Quantitative Sensory Test
(QST) in patients and healthy controls. Bars represent the standard
error of the mean (S.E.M.). Asterisks positioned above the bars indicate a
significant difference (P<0.05) between the MEP amplitude before and
after QST. (B) Reduction in pain intensity during the Conditioned Pain
Modulation (CPM). The pain on the numeric rating scale (NRS) from 0 to
10 is presented during the test stimulus (QST) and during the
conditioning stimulus (cold-pressor task, CPM-TASK). Bars express
the standard error of the mean (S.E.M.) (n=47). Asterisk positioned
above the bars indicate a significant difference (P<0.05) between the
NRS during the CPM.
Table 3 Measurements of motor cortex parameters using transcranial magnetic stimulation (n = 47)
Cortical excitability measures
Before QST evoked pain After QST evoked pain
Mean±SD Median (Q25, Q75) Mean±SD Median (Q25, Q75)
Motor Threshold (MT) 42.65 (7.39) 41 (37.5, 46) —— ———
Motor evoked potential (mV) 1.74 (0.71) 1.53 (1.27, 2.20) 2.13 (0.93) 1.93 (1.58, 2.58)
Intracortical Facilitation (ratio: ICF/test stimulus) 1.16 (0.42) 1.11 (1, 1.23) 1.25 (0.59) 1.15 (0.92, 1.44)
Short Interval Intracortical Inhibition (ratio: SICI/test stimulus) 0.32 (0.14) 0.28 (0.22, 0.35) 0.34 (0.19) 0.29 (0.21, 0.43)
Cortical Silent Period (CSP) 65.42 (19.64) 66.25 (47.9, 79.31) 66.16 (20.16) 68.30 (50.59, 81.71)
(Motor evoked potential: MEP); Interquartile interval (Q); Intra-cortical inhibition (ICI) expresses the relationship between the amplitude of wave and motor evoked
potentials (relative amplitude, express in%), at inter-stimuli intervals (ISIs) of 2 ms with paired-pulse. The first is a sub-threshold stimulus [80% of the rest motor threshold
(rMT)] followed by the second one which is a suprathreshold stimulus (130% rMT). (B) Cortical silent period (CSP) expressed in milliseconds (ms); (C) Motor-evoked
potentials (MEP) expressed in mV, evoked by a stimulus of 130% the intensity of the rMT, and should have peak-to-peak MEP amplitude of at least 1 mV.
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http://www.biomedcentral.com/1471-2202/15/42Table 4 Multivariate linear regression analysis of the relationship between trait anxiety and motor cortex excitability
before QST evoked pain (n= 47)
Dependent variable Type III sum of squares df Mean square error F P Partial eta squared
Motor threshold 256.75 4 64.19 1.12 0.36 0.10
Motor evoked potential 1.93 4 0.48 0.87 0.48 0.08
Intracortical facilitation 6.25 4 1.56 5.69 0.001* 0.37
Short intracortical inhibition 0.228 4 0.057 3.61 0.01* 0.28
Cortical silent period 5466.5 4 1366 5.67 0.001* 0.37
β SEM t P Partial eta squared
Motor threshold
Trait-anxiety −0.06 0.17 −0.38 0.70 0.004
Age (years) 0.17 0.09 1.84 0.07 0.08
B-PCP:S 0.09 0.07 1.36 0.18 0.04
Motor evoked potential
Trait-anxiety −0.02 0.02 −0.78 0.44 0.02
Age (years) −0.01 0.009 −1.37 0.17 0.04
B-PCP:S −0.007 0.007 −1.05 0.29 0.03
Intracortical Facilitation
c
Trait-anxiety 0.05 0.012 4.06 0.00* 0.29
Age (years) −0.008 0.007 −1.19 0.23 0.03
B-PCP:S −0.004 0.005 −0.77 0.45 0.01
Short intracortical inhibition
c
Trait-anxiety 0.001 0.003 0.32 0.75 0.003
Age (years) 0.00 0.002 0.21 0.83 0.001
B-PCP:S −0.002 0.001 −1.21 0.23 0.04
Cortical silent period
Trait-anxiety −1.17 0.39 −2.99 0.01* 0.18
Age (years) -.013 0.22 −0.06 0.95 0.00
B-PCP:S −0.163 0.16 −1.02 0.31 0.03
Dependent variable Type III sum of squares df Mean square error F P Partial eta squared
Motor evoked potential 10.48 3 3.49 4.93 0.13 0.12
Intracortical facilitation 4.27 3 1.42 5.08 0.004* 0.27
Short intracortical inhibition 0.04 3 0.012 0.31 0.81 0.02
Cortical silent period 2979.0 3 993.01 2.62 0.06 0.16
β SEM t P Partial Eta Squared
Motor evoked potential
Trait-anxiety −0.04 0.02 −2.01 0.05 0.09
Age (years) −0.006 0.01 −0.53 0.59 0.01
B-PCP:S −0.04 0.08 −0.28 0.78 0.01
Intracortical facilitation
c
Trait-anxiety 0.04 0.01 3.09 0.01* 0.19
Age (years) 0.002 0.007 0.32 0.75 0.01
B-PCP:S 0.02 0.005 3.16 0.01* 0.19
Short intracortical inhibition
c
Trait-anxiety 0.003 0.005 0.57 0.57 0.008
Age (years) 0.00 0.003 −0.07 0.95 0.001
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http://www.biomedcentral.com/1471-2202/15/42observation, as NMDA receptor antagonists (i.e. dextrome-
thorphan) decrease ICF [38]. Likewise, GABA-A agonists
like benzodiazepines (e.g. Lorazepam) and barbiturates de-
crease the SICF. This supports the hypothesis that the first
pulse elicits the GABA-A receptor-mediated short latency
inhibitory postsynaptic potential (PSPs) in corticospinal
and/or first order excitatory interneurons that inhibits the
facilitatory interactions with the second pulse [39]. On the
other hand, GABA-B agonists (e.g. Baclofen) increase ICF
[40]. It has also been suggested that ICF is not exclusively
mediated by excitatory interneurons, but rather by a bal-
ance between inhibition and excitation [38].
Finally, the duration of the cortical inhibition assessed
by CSP is consistent with intracellular measurements of
the inhibitory PSPs from the stimulation of the GABA-A
receptor [41,42]. Also, a short-lasting CSP shortening
after diazepam injection has been reported [43]. It has
been hypothesized that, just after diazepam injection, a
GABA-A mediated inhibition could transiently reduce
facilitatory thalamo-cortical influences on inhibitory inter-
neurons of the motor cortex [43]. Overall, the changes in
the balance between cortical inhibitory and facilitation ob-
served in the present study may be explained by impair-
ments in neurotransmission mediated by GABA-B and
NMDA receptors [44].
We found that trait-anxiety explained about 36% of
the variance of the MEP amplitude induced by QST
evoked pain. Patients with high trait-anxiety might have
less corticospinal modulation of the pain response dur-
ing QST, which also made them present higher motor
cortex excitability. Furthermore, it is unlikely that time
or other non-specific effects of the QST intervention might
have influenced the cortical excitability parameters, because
healthy controls MEPs remained unchanged after the QST
intervention. This finding is in agreement with previous
reports that showed a short latency during a stimulus on
peripheral sensory nerves induced by QST in anxious
subjects [45]. Previous reports had consistently described
increments on MEP after painful experiences [46-48] and
under experimental pain [48-51]. To the best of our know-
ledge, the present study is the first assessment of the associ-
ation between anxiety and MEP changes in patients with
chronic pain submitted to standardized nociceptive stimuli.
Thereby this finding suggests that the inhibitory capacity of
the corticospinal modulator system is reduced. In fact, this
effect in chronic pain patients underscores dysfunctional
cortical processing in these subjects, because the motor re-
actions to pain in healthy controls result in the suppression
of MEP amplitude from all distal hand muscles [48-51].
Another potential explanation to be considered is the po-
tential protective effect of emotional amplification on pain
consistent with the Gray–McNaughton theory, which pro-
poses that during anxiety the hippocampal formation in-
creases the valence of aversive events to prime behavioral
responses adaptive to the worst possible outcome. It has
been described that the hippocampal formation is respon-
sible for increased pain by amplifying signals to the neural
representation of the painful stimulus [52]. In fact this
response may change overall processing of pain on the
inhibitory system as compared to experimental pain
(or acute pain) in healthy subjects. Overall, our observa-
tions help to interpret the electrophysiological evidence
for the relationship between psychological symptoms
and pain modulation.
Furthermore, it was also observed that the interaction
between pain and anxiety reduced the CPM during the
QST evoked pain. Considering that the CPM evaluates
the function of the corticospinal system, a lower pain
threshold was observed when the high trait-anxiety was
concurrently with high DRP, this suggest that the func-
tion of the descending modulatory system was reduced.
Such a finding is in agreement with previous reports in
other chronic pain conditions, such as temporoman-
dibular disorder [53]; fibromyalgia [54,55]; tension-type
headache [56]; migraine [57] and also in healthy subjects
with significant pain history [58]. Overall, these findings
indicate that the impact of trait-anxiety on pain is linked
with the central sensitization of nociceptive neurons,
which contribute to the worsening of chronic pain
symptoms. Nevertheless, when assessing the association
between trait-anxiety and Diffuse Noxious Inhibitory
Control (DNIC) induced by the immersion of one’s
hand at 12°C [58,59]. Edwards et al did not find an asso-
ciation between the extent of endogenous analgesia
(tested by DNIC) and psychological parameters, includ-
ing the profile of mood states, locus of control, level of
vigilance, and stress. Such divergence between our find-
ings and those of Edwards et al. [58,59] could be
Table 4 Multivariate linear regression analysis of the relationship between trait anxiety and motor cortex excitability
before QST evoked pain (n= 47) (Continued)
B-PCP:S −0.002 0.002 −0.88 0.38 0.01
Cortical silent period
Trait-anxiety −1.23 0.45 −2.72 0.01* 0.15
Age (years) −0.08 0.26 −0.31 0.75 0.002
B-PCP:S 0.05 0.18 0.25 0.80 0.001
bProfile of Chronic Pain: Screen for a Brazilian population (B-PCP:S);
c(ratio: ICF/test stimulus; ratio: SICI/test stimulus). *P< 0.05.
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clusion of healthy male subjects), the intensity of the
stimuli used (12°C vs. 0°C) and type of assessment
conducted.
We observed not only evidence of increased central
sensitization in chronic pain associated with anxiety but
also a negative impact of trait-anxiety on the endogen-
ous modulatory system in patients with long-term pain
associated with higher levels of disability. Thus, a poten-
tial mechanism to explain such effects may be related to
a change in the neural response from amygdala. Healthy
subjects’ pain modulation is attributed to endogenous
opioid activity activated by the amygdala [60]. The amyg-
dala is directly connected to brainstem structures respon-
sible for the descending modulation, which is at the same
time regulated by endogenous opioid activity [60]. Thus, in
patients with chronic pain, although greater activation of
the amygdale might occur, a reduced opioid activity is
expected because of the central sensitization induced by
the chronic condition, leading to an attenuated endogenous
analgesic response [61]. Such hypothesized explanatory
mechanisms for our observations presented here might
make us consider the endogenous modulation system as a
potential target for specific approaches in chronic pain con-
trol in the context of higher anxiety levels.
This study has some limitations. First, the use of TMS
for neurophysiological assessments involved the evalu-
ation of neurotransmitter system activity in an indirect
manner, and it has been shown to have relatively low
specificity. However, TMS provides a useful tool for
neurophysiological assessment because it induces activity
and evaluates a subject’s response. Second, we included
only female subjects, although an enhanced pain re-
sponse in females has been attributed to physiological
and psychological variables, including mechanisms of
endogenous inhibition, the capability to endure pain,
genetic factors, pain expectation and personality traits
[62,63]. In this context, the gender may be an important
confounding factor because the amygdala is more prone
to activation upon negative emotional responses (i.e.,
stress, fear, and anxiety) in females [64]. Another factor
to consider is the hormonal variation throughout the
menstrual cycle. Although this factor is a possible con-
founder, the effect of estrogen levels on the MEP after
QST evoked pain can be minimized because each pa-
tient served as her own control. Third, another limita-
tion to be considered is the way our team evaluated the
Table 5 Relationship between CPM, trait-anxiety level and pain on the B-PCP:S (n =47)
Source Type III sum of squares df Mean square error F P
Corrected model 24327.85 4 26219.170 2.05 0.10
Dependent variable: Percentage of change in the pain score on numerical pain scale during CPM-TASK
a
Parameter β SEM T P Partial eta squared
Intercept 458.80 221.72 2.07 0.04 0.02
B-PCP:S
b −10.56 3.82 −2.76 0.01 0.15
Trait-anxiety −21.55 10.72 −2.01 0.05 0.09
B-PCP:S* Trait-anxiety 0.39 0.17 2.38 0.02 0.12
Analgesic dose used weekly
c −0.03 0.05 −0.07 0.94 0.00
aConditional pain modulation (CPM).
bProfile of Chronic Pain: Screen for a Brazilian population (B-PCP:S).
bNumber of days analgesics were used per week in the last three months (< 4 times/≥ 4 times).
Figure 4 Relationship between the percentage of pain reduction
during the cold-pressor task (CPM-TASK on the numerical pain
scale (NPS (0-10)) and the Disability related to pain (DRP) (A),
and the trait-anxiety (B), (n=47).
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http://www.biomedcentral.com/1471-2202/15/42use of analgesics because it is always possible to face a
memory bias when inquiring patients about past events.
It is possible that those experiencing more pain, or those
with higher anxiety traits, would report a higher require-
ment of analgesics than those who were less anxious or
experiencing less pain. Fourth, although we recruited
healthy volunteers to assess the potential effect of time
during the experiment, it is worth noting that our con-
trol sample was younger on average. Nevertheless, age
only showed an effect on the motor threshold in the re-
gression models, but not in the other cortical excitability
parameters. Thus, it is unlikely that controls’ age would
modify the present findings. Finally, it would be worth-
while to design similar studies to investigate anxiety’s
effect on other chronic pain syndromes to confirm the
findings revealed in the present study because our con-
clusions can only be claimed as valid in similar severe
chronic MPS samples. Fifth, chronic pain is strongly
associated with anxiety symptoms; this potential con-
founding factor cannot be fully controlled, as it is part
of chronic pain syndromes [65,66]. It is important to
emphasize that in the single-subject design the patients
serve as own control. This design that is sensitive to in-
dividual organism’s differences permits to assess causal
relations between the independent and dependent vari-
ables [67,68]. Whereas it reduces the potential of com-
paring with healthy subjects, it is an ideal strategy to
validate results because in real life a scenario is complex
to find controls that match with the profile of the
chronic pain patients.
Conclusions
In conclusion, we showed that when the chronic MPS
concurs with high trait-anxiety and higher DRP pain, an
imbalance occurs between excitatory and inhibitory im-
pulses in the descending systems to the dorsal horn (as
indexed by ICF, CSP and MEP change upon pain); thus
providing further support to the effects of the emotional
system on central sensitization and also to the potential
mechanisms of decreased pain modulation in chronic pain.
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